Clinical Research Partners, LLC | Forest Avenue, Richmond, VA
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of the study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1345 in children aged 2 to <5 years (Cohort 1 and Cohort 3) and in children at high risk of respiratory syncytial virus (RSV) disease 5 to <18 years of age (Cohort 2) to inform the dose level selection for the next phase of development (Phase 3).
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Cohort 1 and Cohort 3:
Cohort 2:
Key Exclusion Criteria (All Cohorts):
Note: Other protocol-defined inclusion and exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
400 participants in 3 patient groups
Loading...
Central trial contact
Moderna Clinical Trials Support Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal